Cover Image
市場調查報告書

電位控制鉀離子通道亞族A/子類3:開發中產品分析

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364859
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
電位控制鉀離子通道亞族A/子類3:開發中產品分析 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 61 Pages
簡介

本報告提供以電位控制鉀離子通道亞族A子類3為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

電位控制鉀離子通道亞族A子類3:概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Axxam SpA
  • Bionomics Limited
  • conoGenetix biosciences GmbH
  • Johnson & Johnson
  • Kineta, Inc.
  • Sevion Therapeutics, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0149TDB

Summary

Global Markets Direct's, 'Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016', provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
  • The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview
  • Therapeutics Development
    • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development
    • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area
    • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance
    • Early Stage Products
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Universities/Institutes
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Axxam SpA
    • Bionomics Limited
    • conoGenetix biosciences GmbH
    • Johnson & Johnson
    • Kineta, Inc.
    • Sevion Therapeutics, Inc.
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles
    • BNC-164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cgtx-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cgtx-F - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cgtx-G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPI-150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPI-190 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSK-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects
  • Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Featured News & Press Releases
    • Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus
    • May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus
    • May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference
    • Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases
    • Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases
    • Nov 10, 2015: Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus
    • Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting
    • Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation
    • Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus
    • Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting
    • Jun 05, 2015: Sevion Therapeutics to Present at International Antibody Meeting
    • May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases
    • May 04, 2015: Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015
    • Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease
    • Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Axxam SpA, H1 2016
  • Pipeline by Bionomics Limited, H1 2016
  • Pipeline by conoGenetix biosciences GmbH, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Kineta, Inc., H1 2016
  • Pipeline by Sevion Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top